Ascendis Pharma Announces The FDA Accepts For Review Resubmitted NDA For TransCon PTH In Adult Patients With Hypoparathyroidism
Portfolio Pulse from Benzinga Newsdesk
Ascendis Pharma A/S announced that the FDA has accepted for review the resubmitted NDA for TransCon PTH for treating adult hypoparathyroidism, with a PDUFA goal date of May 14, 2024.
December 11, 2023 | 1:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ascendis Pharma's resubmitted NDA for TransCon PTH has been accepted by the FDA, indicating progress towards potential approval.
The acceptance of the NDA by the FDA is a positive development for Ascendis Pharma, as it moves the company closer to potentially bringing TransCon PTH to market. This could lead to increased investor confidence and a positive short-term impact on the stock price, given the significance of new drug approvals in the biotech industry.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100